# Table of Contents

## Highlights

### 761 Selected Articles from This Issue

## Small Molecule Therapeutics

### 763 Discovery of JNJ-63576253, a Next-Generation Androgen Receptor Antagonist Active Against Wild-Type and Clinically Relevant Ligand Binding Domain Mutations in Metastatic Castration-Resistant Prostate Cancer


### 775 The Discovery of a Novel Antimetastatic Bcl3 Inhibitor


### 787 The Monoacylglycerol Lipase Inhibitor JZL184 Inhibits Lung Cancer Cell Invasion and Metastasis via the CB1 Cannabinoid Receptor

Jan Lukas Prüser, Robert Ramer, Felix Wittig, Igor Ivanov, Jutta Merkord, and Burkhard Hinz

### 803 Targeting EYA3 in Ewing Sarcoma Retards Tumor Growth and Angiogenesis

Yuhua Wang, Ram Naresh Pandey, Kaushik Roychoudhury, David Milewski, Tanya V. Kalin, Sara Szabo, Joseph G. Pressey, and Rashmi S. Hegde

### 816 Identification and Characterization of IMD-0354 as a Glutamine Carrier Protein Inhibitor in Melanoma

Yongmei Feng, Gaurav Pathria, Susanne Heynen-Genel, Michael Jackson, Brian James, Jun Yin, David A. Scott, and Ze’ev A. Ronai

## Large Molecule Therapeutics

### 833 Taxanes Sensitize Prostate Cancer Cells to TRAIL-Induced Apoptotic Synergy via Endoplasmic Reticulum Stress

Korie A. Grayson, Jacob M. Hope, Wenjun Wang, Cynthia A. Reinhart-King, and Michael R. King

### 846 Robust Antitumor Activity and Low Cytokine Production by Novel Humanized Anti-CD19 CAR T Cells


### 859 A Novel Antibody-IL15 Fusion Protein Selectively Localizes to Tumors, Synergizes with TNF-based Immunocytokine, and Inhibits Metastasis

Riccardo Corbellari, Marco Stringhini, Jaqueline Mock, Tiziano Ongaro, Alessandra Villa, Dario Neri, and Roberto De Luca

### 872 Shaping Functional Avidity of CAR T Cells: Affinity, Avidity, and Antigen Density That Regulate Response

Raanan Greenman, Yoav Pizem, Maya Haus-Cohen, Alona Goor, Guy Horev, Galit Denkberg, Keren Sinik, Yael Elbaz, Vered Bronner, Anat Gliberson Levin, Galit Horn, Shai Shen-Orr, and Yoram Reiter

See related article, p. 946

### 885 Dolaflexin: A Novel Antibody–Drug Conjugate Platform Featuring High Drug Loading and a Controlled Bystander Effect

Aleksandr V. Yurkovetskiy, Natalya D. Bodyak, Mao Yin, Joshua D. Thomas, Susan M. Clardy, Patrick R. Conlon, Cheri A. Stevenson, Alex Ut tard, LiuLiang Qin, Dmitry R. Gumerov, Elena Ter-Ovanesyan, Charlie Bu, Alex J. Johnson, Venu R. Gujrjala, Dennis McGillicuddy, Michael J. DeVit, Laura L. Poling, Marina Protopopova, Ling Xu, Qingxin Zhang, Peter U. Park, Donald A. Bergstrom, and Timothy B. Lowinger
TABLE OF CONTENTS

896 The Dolaflexin-based Antibody-Drug Conjugate XMT-1536 Targets the Solid Tumor Lineage Antigen SLC34A2/NaPi2b

Natalya D. Bodyak, Rebecca Mosher, Aleksandr V. Yurkovetskiy, Mao Yin, Charlie Bu, Patrick R. Conlon, Damon R. Demady, Michael J. DeVit, Dmitry Gumerov, Venu Gurijala, Winnie Lee, Dennis McGillicuddy, Peter U. Park, Laura L. Poling, Marina Protopova, Liu Liang Qin, Cheri A. Stevenson, Elena Ter-Ovanesyan, Alex Utard, Dongmei Xiao, Jian Xu, Ling Xu, Donald A. Bergstrom, and Timothy B. Lowinger

906 Interleukin-4 Receptor Inhibition Targeting Metastasis Independent of Macrophages

Megan M. Cleary, Narendra Bharathy, Jini Abraham, Jin-Ah Kim, Erin R. Rudzinski, Joel E. Michalek, and Charles Keller

915 Antitumor Activity of NLG207 (Formerly CRLX101) in Combination with Enzalutamide in Preclinical Prostate Cancer Models


925 Preclinical Assessment of AMG 596, a Bispecific T-cell Engager (BiTE) Immunotherapy Targeting the Tumor-specific Antigen EGFRvIII

Alexander Sternjak, Fei Lee, Oliver Thomas, Mercedesz Balazs, Joachim Wahl, Grit Lorenczewski, Ines Ullrich, Markus Muenz, Benno Rattel, Julie M. Bailis, and Matthias Friedrich

CANCER BIOLOGY AND TRANSLATIONAL STUDIES

934 PGE2 Released by Pancreatic Cancer Cells Undergoing ER Stress Transfers the Stress to DCs Impairing Their Immune Function

Maria Saveria Gilardini Montani, Rossella Benedetti, Silvia Piconese, Fabio Maria Pulcinelli, Anna Maria Timperio, Maria Anele Romeo, Laura Masuelli, Maurizio Mattei, Roberto Bei, Gabriella D’Orazi, and Mara Cirone

MODELS AND TECHNOLOGIES

946 Phenotypic Models of CAR T-Cell Activation Elucidate the Pivotal Regulatory Role of CAR Downmodulation

Raanan Greenman, Yoav Pizem, Maya Haus-Cohen, Guy Horev, Galit Denkberg, Shai Shen-Orr, Jacob Rubinstein, and Yoram Reiter

See related article, p. 872

ABOUT THE COVER

In this month’s cover, Dwivedi and colleagues demonstrate the binding of a single chain variable fragment (scFv) of the humanized anti-CD19 CAR with CD19 target antigen, obtained through molecular modelling. The unique composition of amino acid residues of the framework region as well as the complementary determining regions (CDRs) of the scFv resulted into the scFv interaction to the CD19 antigen with high binding affinity and with high structural flexibility. Further preclinical and ex vivo studies confirmed that the distinct structural modification in CAR design confers the novel humanized anti-CD19 CAR with a favorable balance of efficacy to toxicity. Read the article on page 846.
# Molecular Cancer Therapeutics

## 20 (5)

*Mol Cancer Ther* 2021;20:761-957.

**Updated version**
Access the most recent version of this article at:
http://mct.aacrjournals.org/content/20/5

<table>
<thead>
<tr>
<th>E-mail alerts</th>
<th>Sign up to receive free email-alerts related to this article or journal.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reprints and Subscriptions</td>
<td>To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at <a href="mailto:pubs@aacr.org">pubs@aacr.org</a>.</td>
</tr>
<tr>
<td>Permissions</td>
<td>To request permission to re-use all or part of this article, use this link <a href="http://mct.aacrjournals.org/content/20/5">http://mct.aacrjournals.org/content/20/5</a>. Click on &quot;Request Permissions&quot; which will take you to the Copyright Clearance Center's (CCC) Rightslink site.</td>
</tr>
</tbody>
</table>